SUPPORT A NEW PHASE 0/11 CLINICAL TRIAL TESTING A FIRST-IN-CLASS TARGETED INHIBITOR FOR A MOLECULAR SUBSET OF RECURRENT GLIOBLASTOMA PATIENTS WITH THE HIGHEST LIKELIHOOD OF DRUG EFFECT.